Download PDF
Onkologische Welt 2010; 01(04): 172-175
DOI: 10.1055/s-0038-1632839
Knochentumoren
Schattauer GmbH

Der Riesenzelltumor des Knochens

The giant cell tumour of bone
A. A. Kurth
1   Klinik für Orthopädie und orthopädische Chirurgie, Universitätsmedizin, Johannes Gutenberg Universität, Mainz
,
B. Sanner
1   Klinik für Orthopädie und orthopädische Chirurgie, Universitätsmedizin, Johannes Gutenberg Universität, Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
03 February 2018 (online)

    Permissions and Reprints

Zusammenfassung

Der Riesenzelltumor ist einer der häufigeren benignen Tumoren des Skelettsystems. Der Tumor ist sehr gut definiert anhand der konventionellen Radiologie, des histologischen Bilds, und der spezifischen anatomischen Lokalisationen in der Epiphyse langer Röhrenknochen. Trotz seiner histologischen benignen Morphologie hat er ein lokal aggressives destruierendes Verhalten mit einer hohen Lokalrezidivrate nach chirurgischer Therapie. In seltenen Fällen kommt es auch zu maligner Entartungen, die bis zum Tod führen kann. Die intraläsionale oder En-bloc-Resektion des Tumors ist die Standardtherapie. Neben dem konsequenten chirurgischen Vorgehen werden seit Neuestem auch systemische und tumorspezifische lokale Verfahren überprüft, um die Rezidivrate zu verringern.

Summary

Giant cell tumour of bone is one of the more common benign tumours of bone. The tumour is well defined in radiography and histological appearance as well as in its anatomic occur-rence in the epiphysis of long bones. Despite histological benign morphology it shows a high local aggressive behaviour and a high recurrence rate after surgery. Surgery is still the treatment of choice, but recently pharmacological approaches under investigation which might reduce recurrence rate.

Schlüsselwörter

Riesenzelltumor

Keywords

Giant cell tumour
 

  • Literatur

  • 1 Abernethy J. Surgical observations on tumors. London, England: Longman and Rees; 1804
    Google Scholar
  • 2 Balke M. et al. Treatment options for recurrent giant cell tumors of the bone. J Cancer Res Clin Oncol 2009; 135: 149-158.
    CrossrefPubMedGoogle Scholar
  • 3 Becker WT. et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008; 90: 1060-1067.
    CrossrefPubMedGoogle Scholar
  • 4 Bloodgood JC. Benign giant-cell tumor of bone: Its diagnosis and conservative treatment. Am J Surg 1923; 37: 105-116.
    Google Scholar
  • 5 Campanacci M. Bone and soft tissue tumors. New York: Springer Verlag; 1999: 99-142.
    CrossrefGoogle Scholar
  • 6 Cheng YY. et al. Bisphosphonates induce apoptsosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004; 75: 71-77.
    CrossrefPubMedGoogle Scholar
  • 7 Coley BL, Higinbotham NL. Giant cell tumor of bone. J Bone Joint Surg 1938; 20: 870-884.
    Google Scholar
  • 8 Cooper A, Travers B. Surgical Essays. London, England, Cox and Son and Longman and Co, 1818; 1: 186-208.
    Google Scholar
  • 9 Dahlin DC UK. Giant cell tumor (Osteoclastoma). In Dahlin Dc Uk. (ed.) Bone Tumors. Fourth. Springfield: Charles C Thomas; 119-140 1986
    Google Scholar
  • 10 Dorfmann HD, Czerniak B. Giant cell lesions, in Bone Tumors. St. Loius: MO, Mosby; 1998: 559-606.
    Google Scholar
  • 11 Dreinhofer KE. et al. Giant-cell tumours with fracture at diagnosis: Curettage and acrylic cementing in ten cases. J Bone Joint Surg 1995; 77: 189-193.
    PubMedGoogle Scholar
  • 12 Durr HR. et al. Phenol as an adjuvant for local control in the treatment of giant cell tumor of the bone. Eur J Surg Oncol 1999; 25: 610-618.
    CrossrefPubMedGoogle Scholar
  • 13 Eckardt JJ, Grogan TJ. Giant cell tumor of bone. Clin Orthop 1986; 204: 45-58.
    Google Scholar
  • 14 Enneking WF. Staging benign lesions, in Musculoskeletal Tumor Surgery. New York, NY: Churchill Livingstone; 1983: 87.
    Google Scholar
  • 15 Gamberi G. et al. Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone. Ann Oncol 2004; 15: 498-503.
    CrossrefPubMedGoogle Scholar
  • 16 Grano M. et al. Functional and biochemical characterization of osteoclast-like cells derived from giant cell tumors of bone. Boll Soc Ital Sper 1992; 68: 249-253.
    PubMedGoogle Scholar
  • 17 Gross SA. Sarcoma of the long bone: Based upon a study of one hundred and seventy-five cases. Am J Med Sci 1879; 155: 2-57.
    Google Scholar
  • 18 Hu Y, Yu S. Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. Zhonghua Bing Li Xue Za Zhi 2002; 31: 128-131.
    PubMedGoogle Scholar
  • 19 Jaffe HL. et al. Giant cell tumor of bone: Its pathologic appearance, grading, supposed variants and treatments. Arch Pathol 1940; 30: 993-1031.
    Google Scholar
  • 20 Kafchitsas K. et al. Rezidivhäufigkeit des Riesenzelltumors nach verschiedenen Therapiestrategien. Z Orthop 2002; 140: 75.
    Google Scholar
  • 21 Kumta SM. et al. Expression of VEGF and MMP-9 in giant cell tumor of bone and orther osteolytic lesions. Life Sci 2003; 73: 1427-1436.
    CrossrefPubMedGoogle Scholar
  • 22 Lindeman JH. et al. Cathepsin K is the principal pro-tease in giant cell tumor of bone. Am J Pathol 2004; 165: 593-600.
    CrossrefPubMedGoogle Scholar
  • 23 Marcove RC. et al. Giant-cell tumors treated by cryo-surgery: A report of twenty-five cases. J Bone Joint Surg 1973; 55A: 1633-1644.
    Google Scholar
  • 24 McCarthy EF. Giant-cell tumor of bone: An historical perspective. Clin Orthop Relat Res 1980; 153: 14-25.
    Google Scholar
  • 25 Myerding HW. Benign and malignant giant cell tumor of bone: Diagnosis and results of treatment. JAMA 1941; 117: 1849-1855.
    CrossrefGoogle Scholar
  • 26 Morgan T. et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005; 167: 117-128.
    CrossrefPubMedGoogle Scholar
  • 27 Nelaton E. D´une nouvelee espèce de tumeurs bènignes des os, ou tumeurs à myèloplaxes. Paris: France Adrien Delahaye; 1860
    Google Scholar
  • 28 Paget J. Lectures in Surgical Pathology. London, England: Brown, Green and Longman; 1853: 446.
    Google Scholar
  • 29 Roux S. et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expresses in giant cell tumors of bone. Am J Clin Pathol 2002; 117: 210-216.
    CrossrefPubMedGoogle Scholar
  • 30 Sabokbar A. et al. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 2003; 21: 73-80.
    CrossrefPubMedGoogle Scholar
  • 31 Schajowicz F. Giant cell tumor (osteoclastoma), in tumor and tumorlike lesions of bone and joints. New York, NY: Springer Verlag; 1981: 205-242.
    Google Scholar
  • 32 Seethalakshmi V, Jambhekar NA. Metastatic giant cell tumor of bone: Are there associated factors and best treatment modalities?. CORR epub July 2009
    PubMedGoogle Scholar
  • 33 Skubitz KM. et al. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144: 193-200.
    CrossrefPubMedGoogle Scholar
  • 34 Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508.
    CrossrefPubMedGoogle Scholar
  • 35 Thomas D. et al. Denosumab treatment of giant cell tumor of bone:interim analysis of an open-label phase II study [meeting abstracts]. J Clin Oncol. 2008 26: 10500. The preliminary data from this study indicated that targeting of RANKL is a novel, clinically effective therapeutic strategy in advanced GCT.
    PubMedGoogle Scholar
  • 36 Tse LF. et al. Biophosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008; 42: 68-73.
    CrossrefPubMedGoogle Scholar
  • 37 Virchow R. Die Krankhaften Gewulste. Berlin, Germany: Hirschwald; 1867: 2.
    Google Scholar